on third-trimester exposure on small molecules as fingolimod or dimethyl fumarate is available.
Would it be ethical to include women treated with natalizumab planning a pregnancy in an RCT? The answer again is no. Experiments on humans are ethically permissible only when adherence to the protocol does not conflict with the subjects' (in the case of pregnancy, two subjects) best interest, a maximum benefit with a minimum risk. Often the best interest of one of the two units (mother/embryo fetus) might be contradictory, or in the best case, there might be no theoretical concern for the baby, but not enough data are available to prove this assumption.
While it might be unethical or unfeasible for an investigator to assign a certain exposure to a person, people often willingly or unwillingly expose themselves to potential harmful factors. 3 Therefore, well-designed observational studies using modern statistical methods, for example, disease-specific registries, drug exposure registries, and data linkage of populationbased registries, are necessary to answer urging questions around the complex MS and family planning. 10 The quality of registries is in general higher than data from pharmacovigilance, with many missing data and high numbers of lost to follow-ups. Neurologists can-as the past has shown that pregnancy registries recruit very slowly-support the active participation in those registries with the inclusion of pregnant women. The earlier high-quality data are collected, the sooner a potential risk or non-risk can be communicated with the patient.
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